Halozyme Therapeutics Inc. Stock
A loss of -1.130% shows a downward development for Halozyme Therapeutics Inc..
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
As a result the target price of 76 € shows a slightly positive potential of 6.17% compared to the current price of 71.58 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -1.130% | -0.666% | 4.496% | 36.187% | 22.150% | 83.163% | 105.512% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -1.560% | -3.421% | -5.275% | 86.343% | 5.055% | 103.398% | 189.613% |
| Ionis Pharmaceuticals Inc. | -2.030% | -9.692% | -36.406% | 19.220% | -33.917% | 19.125% | 43.391% |
Comments
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and